Valuation: Cardiol Therapeutics Inc.

Market Cap 312M 222M 194M 182M 166M 21.2B 312M 2.19B 843M 10.82B 833M 814M 34.9B P/E 2026 *
-8.5x
P/E 2027 * -9.42x
Enterprise Value 297M 211M 184M 173M 158M 20.18B 297M 2.08B 803M 10.3B 793M 775M 33.22B EV / Sales 2026 *
-
EV / Sales 2027 * 307x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
08-12 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
05-07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
05-07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
05-07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
04-28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
04-28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
04-01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
04-01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
04-01 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
03-31 Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-10 Cardiol Therapeutics Inc. Announces the Publication of Results from Its Phase II Archer Study in ESC Heart Failure CI
1 day+1.14%
1 week+3.49%
Current month-2.91%
1 month+3.49%
3 months+76.24%
6 months+106.98%
Current year+103.82%
1 week 2.56
Extreme 2.56
2.78
1 month 2.44
Extreme 2.44
3.23
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.19
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 2017-01-18
Director of Finance/CFO - 2018-08-15
Chief Operating Officer - 2020-12-02
Director TitleAgeSince
Director/Board Member - 2017-12-14
Director/Board Member - 2017-01-18
Chairman - 2021-07-06
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Option

Chairman

25,000 0.0214%
9/8/26 Option

Chairman

-25,000 0.0214%
8/28/26 Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%+3.49%+73.38%+111.90% 222M
-0.14%+4.31%+4.19%+29.97% 47.86B
+0.08%+0.16%+43.79%+35.89% 44.46B
+0.66%+6.23%+8.96%+93.14% 41.85B
+0.05%-5.86%+334.27%+542.87% 41.34B
-1.60%+0.56%+10.84%+46.93% 30.04B
+0.96%+1.56%+26.52%+159.67% 17.59B
-0.01%-0.92% - - 15.6B
-0.84%+4.82%+25.40%+43.04% 15.69B
-1.08%+12.11%-10.11% - 13.93B
Average +0.03%+2.97%+57.47%+132.93% 26.86B
Weighted average by Cap. -0.06%+2.14%+68.81%+143.43%

Financials

2026 *2027 *
Net sales - 984K 700K 611K 575K 524K 66.88M 984K 6.9M 2.66M 34.15M 2.63M 2.57M 110M
Net income -36.31M -25.81M -22.55M -21.2M -19.34M -2.47B -36.31M -254M -98.17M -1.26B -96.93M -94.8M -4.06B -36.46M -25.92M -22.65M -21.29M -19.43M -2.48B -36.46M -255M -98.58M -1.27B -97.33M -95.19M -4.08B
Net Debt -15.01M -10.67M -9.32M -8.76M -8M -1.02B -15.01M -105M -40.58M -521M -40.06M -39.18M -1.68B -10.26M -7.29M -6.37M -5.99M -5.46M -697M -10.26M -71.86M -27.73M -356M -27.38M -26.78M -1.15B
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
26-09-22 $2.670 +1.14% 237,992
26-09-21 $2.640 +1.15% 202,848
26-09-18 $2.610 -1.14% 879,994
26-09-17 $2.640 +0.76% 221,668
26-09-16 $2.620 +1.55% 302,789
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.670CAD
Average target price
6.000CAD
Spread / Average Target
+124.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRDL Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!